

15 December 2009

Proposal relating to the listing of flecainide acetate

PHARMAC is seeking feedback on a provisional agreement with Douglas Pharmaceuticals Limited relating to the listing of flecainide acetate (Tambocor and Tambocor CR) in the Pharmaceutical Schedule.

Flecainide acetate is used for the prevention of supraventricular and ventricular arrhythmias.

Details of the Proposal

This proposal would result in the price and subsidy for Tambocor and Tambocor CR being amended in Section B and in Part II of Section H of the Pharmaceutical Schedule (ex-manufacturer and exclusive of GST) from 1 February 2010 as follows:

Chemical	Presentation	Brand	Pack size	Current price and subsidy	Proposed price and subsidy
Flecainide acetate	Tab 50 mg	Tambocor	60	\$42.82	\$45.82
Flecainide acetate	Tab 100 mg	Tambocor	60	\$75.63	\$80.92
Flecainide acetate	Cap long-acting 100 mg	Tambocor CR	30	\$42.82	\$45.82
Flecainide acetate	Cap long-acting 200 mg	Tambocor CR	30	\$75.63	\$80.92
Flecainide acetate	Inj 10 mg per ml, 15 ml	Tambocor	5	\$49.02	\$52.45

Tambocor and Tambocor CR would have subsidy and delisting protection until 31 January 2014.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 8 January 2010** to:

Stephen Woodruffe	Email: stephen.woodruffe@pharmac.govt.nz
Therapeutic Group Manager	Fax: 04 460 4995
PHARMAC	Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.